Pierre Squifflet

694 total citations
20 papers, 406 citations indexed

About

Pierre Squifflet is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Pierre Squifflet has authored 20 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Immunology and 5 papers in Hematology. Recurrent topics in Pierre Squifflet's work include Cancer Treatment and Pharmacology (6 papers), Phagocytosis and Immune Regulation (6 papers) and HER2/EGFR in Cancer Research (4 papers). Pierre Squifflet is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Phagocytosis and Immune Regulation (6 papers) and HER2/EGFR in Cancer Research (4 papers). Pierre Squifflet collaborates with scholars based in Belgium, United States and France. Pierre Squifflet's co-authors include Marc Buyse, Emmanuel Quinaux, Sylvie Castaigné, Tomasz Burzykowski, Everardo D. Saad, Stefan Michiels, Silvy Laporte, Jean‐Yves Douillard, Robert Paridaens and Justin F. Gainor and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Pierre Squifflet

20 papers receiving 393 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pierre Squifflet Belgium	12	214	97	95	86	85	20	406
Ariel B. Bourla United States	10	149 0.7×	83 0.9×	89 0.9×	141 1.6×	15 0.2×	17	397
Ratislav Bahleda France	12	218 1.0×	33 0.3×	114 1.2×	128 1.5×	22 0.3×	31	458
Karl Verpoort Germany	7	222 1.0×	123 1.3×	98 1.0×	53 0.6×	28 0.3×	10	370
Edward L. Braud United States	7	148 0.7×	107 1.1×	56 0.6×	147 1.7×	29 0.3×	7	335
Neal P. Christiansen United States	14	158 0.7×	99 1.0×	37 0.4×	74 0.9×	158 1.9×	32	474
Priscilla B. Caguioa Philippines	10	120 0.6×	77 0.8×	37 0.4×	43 0.5×	127 1.5×	20	324
Coralie Poncet France	14	117 0.5×	70 0.7×	131 1.4×	63 0.7×	98 1.2×	55	526
HS Rugo United States	13	459 2.1×	80 0.8×	189 2.0×	199 2.3×	59 0.7×	49	561
Simona Aloe Italy	12	244 1.1×	51 0.5×	94 1.0×	94 1.1×	26 0.3×	16	448
Antoine Italiano France	7	108 0.5×	22 0.2×	35 0.4×	127 1.5×	32 0.4×	28	245

Countries citing papers authored by Pierre Squifflet

Since Specialization

Citations

This map shows the geographic impact of Pierre Squifflet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Squifflet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Squifflet more than expected).

Fields of papers citing papers by Pierre Squifflet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Squifflet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Squifflet. The network helps show where Pierre Squifflet may publish in the future.

Co-authorship network of co-authors of Pierre Squifflet

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Squifflet. A scholar is included among the top collaborators of Pierre Squifflet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Squifflet. Pierre Squifflet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chung, Hyun Cheol, Kyungwon Lee, Justin F. Gainor, et al.. (2021). SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer. Annals of Oncology. 32. S215–S216. 10 indexed citations

Lee, Keun-Wook, Hyun Cheol Chung, Tae Min Kim, et al.. (2021). 498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01. SHILAP Revista de lepidopterología. 6 indexed citations

Suciu, Stefan, Pierre Squifflet, Everardo D. Saad, et al.. (2020). Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors. European Journal of Cancer. 137. 171–174. 11 indexed citations

Kim, Tae Min, Nehal J. Lakhani, Justin F. Gainor, et al.. (2020). ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma. Blood. 136(Supplement 1). 13–14. 23 indexed citations

Chow, Laura Q.M., Justin F. Gainor, Nehal J. Lakhani, et al.. (2020). A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.. Journal of Clinical Oncology. 38(15_suppl). 3056–3056. 18 indexed citations

Lee, Keun-Wook, Hyun Cheol Chung, Won Seog Kim, et al.. (2020). 404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC). Regular and Young Investigator Award Abstracts. A245.2–A246. 1 indexed citations

Saad, Everardo D., Pierre Squifflet, Tomasz Burzykowski, et al.. (2019). Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. The Lancet Oncology. 20(3). 361–370. 49 indexed citations

Kim, Tae Min, Nehal J. Lakhani, Justin F. Gainor, et al.. (2019). A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma. Blood. 134(Supplement_1). 1953–1953. 19 indexed citations

Buyse, Marc, et al.. (2017). The impact of data errors on the outcome of randomized clinical trials. Clinical Trials. 14(5). 499–506. 12 indexed citations

10.

Squifflet, Pierre, Stefan Michiels, David S. Siegel, et al.. (2015). Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 15(11). 680–686. 5 indexed citations

11.

Laporte, Silvy, Pierre Squifflet, Noémie Baroux, et al.. (2013). Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open. 3(3). e001802–e001802. 40 indexed citations

12.

Taı̈eb, Julien, Josep Tabernero, Enrico Mini, et al.. (2012). O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial. Annals of Oncology. 23. iv17–iv17. 4 indexed citations

13.

Buyse, Marc, Stefan Michiels, Pierre Squifflet, et al.. (2011). Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. Haematologica. 96(8). 1106–1112. 30 indexed citations

14.

Buyse, Marc, Pierre Squifflet, Beverly J. Lange, et al.. (2011). Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 117(26). 7007–7013. 56 indexed citations

15.

Buyse, Marc, Pierre Squifflet, Kathryn Lucchesi, et al.. (2011). Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia. Trials. 12(1). 86–86. 7 indexed citations

16.

Squifflet, Pierre, Stefan Michiels, David S. Siegel, et al.. (2011). Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib. Blood. 118(21). 1877–1877. 10 indexed citations

17.

Wildiers, Hans, Patrick Neven, Marie‐Rose Christiaens, et al.. (2010). Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Annals of Oncology. 22(3). 588–594. 22 indexed citations

18.

Wildiers, Hans, Christel Fontaine, Peter Vuylsteke, et al.. (2010). Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 123(2). 463–469. 39 indexed citations

19.

Dirix, Luc, Patrick Neven, A. Prové, et al.. (2008). Delivery of adjuvant sequential dose-dense FEC–Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Research and Treatment. 114(1). 103–112. 22 indexed citations

20.

Buyse, Marc, Pierre Squifflet, Silvy Laporte, et al.. (2008). Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in 7 trials. Journal of Clinical Oncology. 26(15_suppl). 8019–8019. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact